Drugs / Ontunisertib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07672574 | Jul → Dec 2026 expected | Crohn disease | Agomab Therapeutics NV | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07683325 | Oct 2026 → Dec 2028 expected | Crohn disease | Agomab Therapeutics NV | Not yet recruiting | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-10-01 | Agomab Spain S.L.U. | Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn’s Disease agomab.com ↗ |
| 2026-06-23 | Agomab Spain S.L.U. | Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease agomab.com ↗ |
| 2025-11-17 | Agomab Spain S.L.U. | Agomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease agomab.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ontunisertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07672574 ↗ |
| Route | Oral | “Oral capsule” NCT07672574 ↗ |